[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hormone-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hormone-therapy":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,55,85,121,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":39,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100054125","quality-of-life-of-patients-who-have-undergone-bilateral-mastectomy-100054125",false,"NCT07699913","Quality of Life of Patients Who Have Undergone Bilateral Mastectomy","Psychological Experience, Quality of Life, and Patient Satisfaction Following Bilateral Breast Reconstruction After Prophylactic or Therapeutic Mastectomy, Using the BREAST-Q Questionnaire.","RM BREAST Q","Inclusion Criteria:\n\n* Female sex\n* Age ≥ 18 years\n* Bilateral mastectomy\n* Breast reconstruction between January 1, 2015, and January 1, 2026\n* No objection to the study\n\nExclusion Criteria:\n\n* Individual under guardianship or curatorship, or deprived of liberty\n* Reconstruction not completed by January 1, 2026.","FEMALE","18 Years",{"count":20,"type":21},115,"ESTIMATED","OBSERVATIONAL","We therefore aim to determine whether the type of mastectomy (preventive in a high-risk patient or therapeutic in a patient with a history of cancer), as well as the timing (immediate or delayed) and type of breast reconstruction, influence the quality of life and satisfaction of patients who have undergone bilateral mastectomy. The goal of this observational study is thus to measure and compare the quality of life of patients who have undergone bilateral mastectomy using the BREAST-Q questionnaire.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38],"Surgery Date","Age","BMI","Height","Weight","Smoking Status","Hormone Therapy","Chemotherapy","Radiotherapy","Postoperative Complications","Type of Reconstruction (Flap or Implant)","Timing of Reconstruction","Type of Mastectomy (Prophylactic or Therapeutic)","BRCA Mutation",[40,41,42],"Comparative","observational","retrospective","NOT_YET_RECRUITING","2026-07-07",{"date":46,"type":47},"2026-07-13","ACTUAL",{"date":49,"type":21},"2026-07-10",{"date":51,"type":21},"2026-08-20",{"name":53,"class":54},"University Hospital, Grenoble","OTHER",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":18,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100637145","comparing-acupuncture-vs-sham-acupuncture-for-the-management-of-hot-flashes-in-prostate-cancer-patients-receiving-hormone-therapy-100637145","NCT07594002","Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy","Inclusion Criteria:\n\n* Patients with history of prostate cancer with currently receiving hormone therapy or had received hormone therapy in the past two years\n* Hormone therapies may include androgen deprivation therapy ( ADT; e.g., leuprolide, degarelix, or relugolix) or androgen signaling inhibitors (e.g., enzalutamide, apalutamide, or darolutamide) or adrenal steroid synthesis inhibitor (e.g., abiraterone acetate).\n* Patients may also receive additional treatments such as chemotherapy, radioligand therapy or target therapy in combination with hormone therapy.\n* Reports hot flashes at least twice per day. Patients may already be taking medications for hot flashes. There is no limit on the number of hot flash medications they can be using.\n* ECOG performance status =3 (see Appendix A).\n* Patients may participate in other therapeutic clinical trials for the treatment of prostate cancer. They will remain eligible as long as they meet the eligible criteria.\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.\n* Patients with a prior or concurrent malignancy are eligible for this trial.\n* Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Patients can't travel for acupuncture\n* Patients with high bleeding tendency as determined by PI","ALL","99 Years",{"count":64,"type":21},40,"INTERVENTIONAL",[67],"NA","This study is evaluating whether acupuncture may help reduce hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of androgen deprivation therapy (ADT) and may negatively affect sleep, mood, concentration, daily activities, and overall quality of life.\n\nParticipants enrolled in this study will receive acupuncture treatment over a defined treatment period. The study will assess changes in hot flash frequency, severity, and quality of life using patient questionnaires and symptom diaries. Participants will complete a daily hot flash diary during selected 7-day assessment periods and quality-of-life questionnaires during study visits.\n\nThe primary goal of this study is to determine whether acupuncture may improve hot flash symptoms and related quality of life in men undergoing treatment for prostate cancer.",[70,71,31,72],"Accupuncture","Prostate Cancer","Hot Flashes",[71,72,74],"Androgen Deprivation Therapy","2026-05-21",{"date":77,"type":47},"2026-05-27",{"date":79,"type":21},"2026-06-05",{"date":81,"type":21},"2028-05-31",{"name":83,"class":54},"University of Kentucky",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":65,"phases":97,"briefSummary":98,"conditions":99,"keywords":103,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":84},"100631101","comparison-of-oral-dydrogesterone-and-vaginal-progesterone-in-menopausal-hormone-therapy-100631101","NCT07496294","Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy","Comparison of Oral Dydrogesterone and Vaginal Micronized Progesterone Regimens Combined With Transdermal Estradiol in Menopausal Hormone Therapy: A Prospective Randomized Controlled Trial","PRO-MHT","Inclusion Criteria:\n\n* Women aged 45-60 years\n* Postmenopausal status (absence of menstruation for ≥12 months)\n* Intact uterus\n* Presence of menopausal symptoms requiring menopausal hormone therapy\n* Willingness to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Unexplained vaginal bleeding\n* History of breast cancer or endometrial cancer\n* Known hypersensitivity to study medications\n* History of thromboembolic disease (e.g., deep vein thrombosis or pulmonary embolism)\n* Severe liver disease\n* Uncontrolled hypertension\n* Any condition that, in the opinion of the investigator, makes participation inappropriate","45 Years","60 Years",{"count":96,"type":21},200,[67],"Menopause is a natural stage in a woman's life that can be associated with symptoms such as hot flashes, night sweats, sleep problems, and vaginal dryness. Menopausal hormone therapy is commonly used to relieve these symptoms. In women with an intact uterus, progesterone must be used together with estrogen to protect the lining of the uterus.\n\nThe purpose of this study is to compare two commonly used progesterone treatment methods in women receiving menopausal hormone therapy. All participants will use transdermal estradiol gel, and they will be randomly assigned to receive either oral dydrogesterone or vaginal micronized progesterone.\n\nThis prospective randomized controlled study will evaluate the effects of these treatments on endometrial thickness, menopausal symptoms, vaginal health parameters, bleeding patterns, and quality of life over a 12-month follow-up period.\n\nThe results of this study may help determine the most appropriate progesterone regimen for women undergoing menopausal hormone therapy.",[100,101,31,102],"Menopausal Women","Menopausal Symptom Relief","Menopausal Hormone Therapy",[104,105,106,107,108,109,110,111],"Menopausal hormone therapy","Dydrogesterone","Micronized progesterone","Transdermal estradiol","Progesterone route of administration","Endometrial thickness","Postmenopausal women","Randomized controlled trial","2026-03-23",{"date":114,"type":47},"2026-03-27",{"date":116,"type":21},"2026-04",{"date":118,"type":21},"2027-10",{"name":120,"class":54},"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":128,"sex":61,"minAge":18,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":84},"100473251","hormone-therapy-and-angiotensin-dependent-arterial-and-renal-vasoconstriction-in-humans-100473251","NCT05442463","Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans","Hormone Therapy and Angiotensin-Dependent Arterial and Renal","Inclusion Criteria:\n\n* Age 18 to 90 years\n* Taking hormones orally or non-orally (either estrogen, progesterone or testosterone)\n\nExclusion Criteria:\n\n* Cardiovascular disease (symptoms consistent with myocardial ischemia, previously documented myocardial ischemia, cardiac arrhythmias or valve abnormalities, or abnormal ECG at screening)\n* Cerebrovascular disease (transient ischemic attacks or stroke)\n* History of hypertension (BP\\>140\u002F90 or use of antihypertensive medications)\n* Estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73m2\n* Diabetes mellitus (defined by history, use of hypoglycaemic agents or a fasting glucose \\>7mmol\u002FL)\n* Current smoker\n* Previous history of preeclampsia\n* Anabolic steroids, cortical steroids, or non-steroidal anti-inflammatory medications, or at the discretion of the investigator.",true,"90 Years",{"count":96,"type":21},"1. to investigate the association between route of administration of exogenous estrogen (transdermal vs. oral) and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) women.\n2. to investigate the association between exogenous testosterone exposure and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) men.",[31],[134,135,136,137,138,139,140,141],"post menopausal hormone replacement therapy","transgender men","transgender women","nonbinary","cis gender","post menopause","HRT","hormone replacement therapy","RECRUITING","2025-03-24",{"date":145,"type":47},"2025-03-27",{"date":147,"type":47},"2020-11-30",{"date":149,"type":21},"2025-11-30",{"name":151,"class":54},"University of Calgary",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":160,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":65,"phases":163,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100498142","phase-2-a-randomized-study-comparing-the-immune-modulation-effect-of-ribociclib-palbociclib-and-abemaciclib-in-erher2--ebc-100498142","NCT05766410","A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+\u002FHER2- EBC","A Randomized, Open-label, Parallel-group Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in Early ER+\u002FHER2- Breast Cancer","ORACLE-RIPA","Inclusion Criteria:\n\n* Female patients aged ≥ 20 years old at the time of informed consent.\n* Patient has a histologically and\u002For cytologically confirmed diagnosis of estrogen-receptor positive and\u002For progesterone receptor positive breast cancer based on the most recently analyzed tissue sample and all tested by local laboratory. with estrogen receptor positive (\\>10%) on IHC staining and HER2 negative (IHC 0+\u002F1+, or IHC 2+ plus FISH negative)\n* Stage II to III\n* With adequate organ function\n* ECOG 0-1\n\nExclusion Criteria:\n\n* Pregnant or nursing (lactating) women\n* Women of child-bearing potential unless using highly effective methods of contraception during study drug dosing and for 12 months post-dosing\n* Patients with active systemic infections or known to have AIDS or to test positive for HIV antibody at Screening\n* Any other disease or condition that could interfere with participation in the study according to the study protocol, or with the ability of the patients to cooperate and comply with the study procedures.","20 Years",{"count":162,"type":21},60,[164],"PHASE2","The 3 FDA-approved CDK4, 6 inhibitors, palbociclib, ribociclib, and abemciclib, all provided progression-free survival benefits when combined with endocrine therapy in advanced ER+\u002FHER2- breast cancer. But, not all of them provided overall survival benefit in the same setting. One of the proposed mechanisms that influence the overall survival difference is from the different influence of the 3 CDK4, 6 inhibitors on tumor microenvironment and\u002F or immune system. However, there was no head-to-head comparison of the 3 CDK4, 6 inhibitors in the same study. Neoadjuvant therapy provides a window to obtain tissue samples before treatment, during treatment, and after treatment. We aim to compare the immune modulation effects of palbociclib, ribociclib, and abemaciclib with letrozole in neoadjuvant treatment for ER+\u002FHER2- early breast cancer.",[167,168,31],"Breast Cancer","Hormone Receptor-positive Breast Cancer",[170,171,172,168],"CDK4, 6 inhibitor","Neoadjuvant therapy","Hormone therapy","2023-03-15",{"date":175,"type":47},"2023-03-16",{"date":177,"type":47},"2022-09-16",{"date":179,"type":21},"2026-09-30",{"name":181,"class":54},"National Taiwan University Hospital",2]